New IVF treatment could make babies healthier, experts believe

A fertility clinic in Southampton is the first to use the treatment in the UK

The development of a powerful gene-editing technology called Crispr-Cas9 has transformed the ability of geneticists to make changes to the human genome.
The development of a powerful gene-editing technology called Crispr-Cas9 has transformed the ability of geneticists to make changes to the human genome.

A new IVF treatment which allows the egg to be fertilised inside the womb rather than in a laboratory is being offered to potential parents in the UK for the first time.

The method involves inserting a capsule containing egg and sperms cells inside a woman’s womb for 24 hours, enabling the embryo to develop.

Doctors use a 1cm long and 1mm wide device called AneVivo during the procedure. After two to four days, doctors choose embryos which are healthy enough to be implanted into the lining of the womb, where it is hoped they will develop into a foetus.

Experts believe that the new treatment will help improve the birth weights of IVF babies as they remain in the laboratory for a shorter time and are less exposed to synthetic culture fluids.

The method is also thought to lessen the psychological impact of fertility treatment.

Current IVF treatment sees doctors removing eggs from the ovaries and fertilising them with sperm in a laboratory. Doctors then select suitable embryos to insert into the womb.

The AneVivo device

IVF is generally offered to women 43-years-old or younger who have been unable to become pregnant after having unprotected sex for two years, or who have had 12 cycles of artificial insemination, according to the NHS.

This method can involve health risks including side effects such as hot flushes; ectopic pregnancy where the embryos are mistakenly implanted in the fallopian tube; and ovarian hyperstimulation syndrome where too many eggs develop in the ovaries.

The UK's fertility watchdog has approved the new treatment, which costs £700 each time.

The HFEA advisory committee said that while no evidence suggested that the device was ineffective or unsafe, further research was needed to show whether "the process has a greater or lesser efficacy than that of traditional IVF methods", BBC News reported.

Professor Nick Macklon, medical director at Complete Fertility Centre Southampton, located at the city's Princess Anne Hospital, helped to develop the device.

He said the use of the AneVivo device "signals a real breakthrough in IVF treatment" as it enables women to carry the embryo in the early stages of development.

"That is important psychologically as it involves parents-to-be directly with the fertilisation process and early embryo development but, perhaps more importantly, it also could provide many potential health benefits for babies born following fertility treatment."

Prof Macklon, who is also chairman in obstetrics and gynaecology at the University of Southampton, added: "This is a very significant moment in the advancement of fertility treatment in the UK and we are all extremely excited to be able to offer patients the option of a more natural fertilisation process."

Additional reporting by PA

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Please enter a valid email
Please enter a valid email
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Please enter your first name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
Please enter your last name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
You must be over 18 years old to register
You must be over 18 years old to register
Opt-out-policy
You can opt-out at any time by signing in to your account to manage your preferences. Each email has a link to unsubscribe.

By clicking ‘Create my account’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Join our new commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in